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ABSTRACT 
 
 
    The pregnane X receptor (PXR or SXR; NR1I2) is a member of the nuclear receptor 
superfamily. It activates the transcription of a large network of genes including 
cytochrome P450 (CYP) and Mdr1 which play critical roles in chemicals metabolism and 
transportation. Induction of CYPs contributes to adverse drug-drug interactions. Non-
toxic, PXR-specific antagonists will be valuable in attenuating the adverse drug-drug 
interaction which is the cause of many treatment failures in clinic. However, few hPXR 
antagonists were reported particularly the specific ones. In this thesis a reporter gene 
assay was used to study the specificity of hPXR antagonists from a panel of compounds 
that have been previously indentified as non-toxic hPXR antagonists. 
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Chapter 1. Introduction 
 
 
Brief Overview on PXR 
 
    Mouse Pregnane X receptor (PXR or SXR; NR1I2), a member of the nuclear receptor 
(NRs) superfamily [1-3], was first cloned and identified in 1998 [4]. The human PXR 
(hPXR) was found subsequently and named steroid and xenobiotic receptor (SXR) or 
pregnane-activated receptor (PAR) [5, 6].  
 
    PXR is composed of four independent but interacting functional modules (Figure 1-1), 
which include, from N-terminus to C-terminus, the modulator domain, the DNA-binding 
domain (DBD), the hinge region and the ligand-binding domain (LBD) [7]. Among these 
domains, DBD mediates the sequence-specific binding to the “response element” of its 
target gene while LBD mediates the ligand-binding, dimerization to other NRs or 
homodimerization and ligand-independent repression [8]. 
 
    PXR has at least three isoforms, PXR.1, PXR.2 and PXR.3. PXR.1 is the most 
abundantly expressed isoform in human tissue. It can be activated by structurally diverse 
lipophilic ligands. PXR.2 mRNA which represents 6.7% of total PXR mRNA transcripts 
is 111 nucleotides shorter than PXR.1, resulting in a deletion of 37 amino acids from the 
PXR LBD. PXR.3 is 41 amino acids shorter than PXR.1 because the 123 nucleotide 
region located in the putative LBD is lost.  Due to the lack of the 41 amino acids, PXR.3 
has a more restricted activation profile than PXR.1 [4]. For example, dexamethasone, 
dexamethasone-t-butyl-acetate, dexamethasone-21-acetate and the pregnenolone 
derivative 6,16α-dimethyl pregnenolone can activate PXR.1. However, among those 
steroids, only dexamethasone-t-butyl-acetate is able to activate PXR.3. Homologous 
comparisons of PXR.3 with different members of nuclear receptors indicate that PXR is 
most like Xenopus laevis orphan nuclear receptor 1(ONR1) and mammalian vitamin D 
receptor (VDR) [9, 10].  
 
    Both PXR.1 and PXR.2 are highly expressed in liver and intestine of embryo and 
adult, and are expressed at a lower level in adult kidney and stomach, but are 
undetectable in other organs [4, 11]. This specific distribution of PXR is highly correlated 
to its versatile functions in regulating dynamic metabolism of a large number of 
endogenous or exogenous nutrients, drugs or other chemicals, because liver and intestine 
are the main organs where many xenobiotics and endobiotics are digested, absorbed, and 
selectively eliminated [11].   
 
 
Functions of PXR  
 
    Generally speaking, PXR can be regarded as an internal sensor for the alterations of 
xenobiotics and endobiotics. Upon binding with diverse natural or synthesized ligands, it 
will form herterodimers with retinoid X receptor (RXR). PXR and RXR heterodimer then 
will probe and bind to the PXR response elements that are located in the 5’ end of the 
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Figure 1-1.  Schematic representation of hPXR multi-domain structure.  hPXR has a 
multi-domain structure which includes a modulatory A/B domain, the DNA-binding 
domain (C domain), the hinge D domain and the ligand-binding domain (E domain) 
which contains a shallow activation function 2 (AF-2) surface essential for ligand-
dependent interactions with transcriptional coregulators. 
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PXR target genes (Figure 1-2). PXR can either promote or block the transcription of 
targeted genes which include but are not limited to P450s from CYP3A and CYP2B, 
transporters such as P-glycoprotein, multidrug resistance-related protein-3, and organic 
anion transporting polypeptide-2 (OATP2) [12-15]. PXR is so important in regulating 
metabolic enzymes and transporters that it inevitably is able to affect the speed at which 
different drugs are digested, absorbed, and eliminated from the body. If different drugs 
are used at the same time and some drugs happen to be PXR ligands with high affinities, 
drug-drug interactions will happen. Drug-drug interactions could accelerate dynamics of 
the drugs which are the substrates of PXR targeted genes-encoded enzymes and lead to 
adverse effects including death.  
 
    Three examples are given here to demonstrate the roles of PXR in drug-drug 
interactions. The first instance is Rifampicin, a drug for long term tuberculosis treatment 
[16]. Moreover, Rifampicin is a human PXR ligand as well. As mentioned previously, 
PXR can regulate CYP3A which can metabolize a lot of drugs which include anti-HIV 
protease inhibitors, oral contraceptives, and midazolam [17-19]. The second example is 
the drug-drug interactions between St John’s Wort, an old herbal medicine for mental 
disorders and nerve pain, and Cyclosporine, an immunosuppressant used in patients who 
received organ transplantation to prevent organ rejection. It has been found that 
components of St John’s Wort contain multiple PXR ligands so that CYP3A activated by 
PXR will speed up cyclosporine metabolism and will lead to transplantation failure [20]. 
The third example is that isoniazid and 3-methylcholanthrene can accelerate the 
metabolism of Acetaminophen (APAP) and cause accumulation of the alkylating 
metabolite N-acetyl-p-benzo-quinone imine (NAPQI) and result in liver damage in a 
PXR-dependent manner [21-23]. Recently, several traditional Chinese medicine (TCMs) 
have also been implicated in drug-drug interactions [24, 25].   
 
    In addition to the xenobiotic functions such as drug-drug interactions discussed 
already, PXR also have important roles in the endobiotic dynamics. Such endobiotic 
associated functions include regulating bile acid detoxification and cholestasis, bilirubin 
detoxification and clearance, adrenal steroid homeostasis and drug–hormone interactions, 
lipid metabolism, inflammation and inflammatory bowel disease, bone homeostasis, and 
retinoic acid metabolism, all of which functions as intensively reviewed[11, 26]. PXR 
activation also up-regulates other drug transporter genes, like Mdr1, Mrp2 and Mrp3 [27]. 
Not only does PXR regulate the expression of so many genes, it also interplays with 
many other nuclear receptors and affects the transcriptional activity thus the expression of 
their target genes. The nuclear receptors that crosstalk with PXR include FXR, GR, CAR, 
VDR, etc.  
 
 
Genetic Variation of Human PXR 
 
    The hPXR gene contains 9 exons, and all exons except exon1 contain coding regions. It 
is located on chromosome 3q12q13.3, with 38 kb length [28]. Similar to mouse PXR, 
hPXR has a few variants. In addition to the three main variants, hPXR.1, hPXR.2 and 
hPXR.3, there are 7 more splice variants with low expression frequency and with 
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Figure 1-2.  Schematic representation of hPXR function.  With ligand binding, PXR 
dimerizes with RXR. RXR/PXR heterodimer binds to the response element of target 
genes, like CYP3A, CYP2B and MDR1 and regulates their transcription.
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unknown function [29]. 
 
    In addition to the splice variants, genetic variations also were found in the hPXR exon 
coding regions.  Heretofore, there are 227 SNPs have been found [26]. Among all the 
exons, so far exon4, encoding the C-terminal portion of the DBD and part of the N-
terminal portion of the LBD, has most identified SNPs. Some SNPs such as P27S can 
affect protein function by either change in hydrophobicity or creation of a serine 
phosphorylation site [28, 30].  The variations become further complicated when genetic 
variants are also found in the promoter region and other non-coding regions of hPXR. 
Probably, those individual variations could account for the different dynamics patterns in 
different patients, when identical drugs were used.  
 
 
PXR Antagonists  
 
    Due to the presence of drug-drug interactions, PXR antagonists seem to be the 
promising small molecules that could block PXR-mediated drug-drug interactions, and 
optimize the efficacy of therapeutics. Designing efficient antagonists against PXR are 
becoming a trend in clinical medicine. Recently, PXR gene activity has been detected in 
endometrial cancer but not normal tissues, highlighting the oncogene-like roles of PXR in 
tumorigenesis. This notion is further supported by the expression of PXR in prostate 
cancer, breast cancer and osteosarcoma tissues, in addition to tumor cell lines [31-34]. In 
prostate cancer cell line PC-3 and endometrial cancer cell line HEC-1, knocking down 
PXR expression by RNA interference (RNAi) has been shown to be a useful approach to 
down-regulate CYP3A4 and MDR1. The diminishment of PXR-mediated expression of 
CYP3A4 and MDR1 significantly increase the therapeutic sensitivities to anticancer 
agents such as paclitaxel and cisplatin, with corresponding reduced drug resistance, as 
already perfectly reviewed [35].   
 
    So far, database of PXR antagonists is expanding. Those antagonists include but are 
not limited to ET-743, some polychlorinated biphenyls, ketoconazole, fluconazole, 
enilconazole, sulforaphane and coumestrol [36-41]. However, it is still elusive whether 
those antagonists, like ET-743, could directly bind to PXR or not. Additionally, 
ketoconazole was shown to function as a wide-range inhibitor for many nuclear receptors 
including PXR, by disrupting NR-co-activator interaction. In contrast, as a PXR 
antagonist, Sulforaphane (SFN) inhibits PXR function by directly binding to PXR [40]. 
Note that SFN still has PXR antagonist independent functions such as histone deacetylase 
inhibition and Phase II enzymes induction. 
 
    The mechanisms through which most current antagonists inhibit PXR function have 
been proposed. The antagonists will bind to the outer surface of PXR at the AF-2 domain 
and compete with PXR required co-activators [42].  Recently, computational methods 
have been used for discovering new antagonists [43]. Because of the promiscuity of 
potential PXR ligands discussed previously, it is difficult to design effective antagonists 
targeting the PXR ligand binding pocket. Therefore, the high-through-put screening of a 
huge pool of pre-generated chemical compounds seems to be a more efficient way to 
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identify some specific PXR antagonists [35]. However, no specific PXR antagonist has 
been identified. Testing the overall effects of those antagonists on PXR functions in vivo 
or whether they really can improve the therapeutic efficacy will rely on the mouse models 
to be discussed.  
 
 
Crosstalk between PXR and other Nuclear Receptors 
 
    There are 48 human nuclear receptors have been identified so far (Figure 1-3). These 
nuclear receptors work in concert with each other in the regulation of gene transcription. 
PXR and some other nuclear receptors work together and form a complex network to 
coordinately regulate metabolism of both xenobiotics and endobiotics, thus protecting 
from diverse groups of adverse chemicals [27]. There are a few types of coordination 
among PXR and other nuclear receptors. First, PXR functions with other nuclear 
receptors to regulate the same target genes. For example, FXR and PXR together can 
form a feedback mechanism to induce CYP3A4 gene expression which in turn can 
regulate bile acid metabolism, thus protecting hepatocytes from toxicity of bile acid. This 
is further supported by the fact that lithocholic acid (LCA) still, to some extent, can 
induce CYP3A4 gene expression in a PXR knockout mouse [44, 45]. Second, activities 
of PXR can be inhibited by target genes of other nuclear receptors.  For example, small 
heterodimer partner (SHP) can inhibit transcriptional activity of PXR in a dose dependent 
manner [46]. Third, activities of PXR can be boosted by other genes. For instance, 
hepatocyte nuclear factor-4 alpha (HNF-4 alpha) is able to induce expression of PXR, 
which is further supported by the phenotypes of the HNF-4 alpha mutant mouse model 
[47]. In addition to the networks discussed above, PXR also interacts with Liver X 
Receptor (LXR), Glucocorticoid Receptor (GR), constitutive androstane Receptor (CAR) 
and Vitamin D Receptor (VDR) [27].  
 
 
PXR Mutant Mouse Models 
 
    Due to the genomic similarities between mouse and human, mouse is a good animal 
model to elucidate the roles of many genes including PXR. So far, there are two kinds of 
PXR mutant models. Each kind has two different lines. The first kind is the PXR knock-
out mouse. Because the PXR-null mice are viable, fertile and have no obvious 
developmental deficiencies, it suggests that PXR is not essential for mouse development 
or physiological homeostasis [48, 49]. However, in contrast with the PXR wild type 
mice, PXR-null mice are no longer responsive to PXR ligands such as PCN.  
 
    Because of the different ligand binding domain (LBD) of PXR between mouse and 
human, some rodent robust PXR ligands, however, are weak for human PXR, and vice 
versa [50]. This will preclude further probing of PXR agonist or antagonist effects using 
mouse models for preclinical implications. To by pass this problem, three PXR 
humanized mouse models were generated. Those humanized PXR mutant mice will no 
longer respond to the rodent-specific PXR ligand PCN. One is Alb-hPXR mice generated 
by cDNA in which Alb-hPXR is restricted in liver [49]. The other is a bacterial artificial  
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Figure 1-3.  Phylogenetic tree of human nuclear receptors (from Wikipedia).  There 
are 48 known human nuclear receptors. PXR interplays with several other nuclear 
receptors including CAR and VDR which belong to the same group as PXR, and those 
from other groups, like GR, RXRα, RXRβ, FXR, PPARγ and LXR.
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chromosome (BAC) transgenic mouse line where PXR gene is under control of the 
endogenous human PXR promoter [51]. The third one is the mouse line where human 
PXR is fused to a viral VP16 coactivator, resulting in a constitutively active form of 
human PXR [52]. The PXR-humanized mice have been shown to be useful models to 
bypass the species differences in response to PXR ligands.  
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Chapter 2. Materials and Methods 
 
 
Reagents 
 
Dulbecco's modified eagle medium (DMEM), phenol red-free DMEM, dialyzed FBS, 
Recovery™ cell culture freezing medium, non-essential amino acids (NEAA), HEPES (1 
M, pH 7.3), penicillin/streptomycin (antibiotics), sodium Pyrurate, Zeocin™, 
Geneticin®, blasticidin, 0.05% trypsin/EDTA, GeneBLAzer® loading kit and 
Dulbecco’s phosphate buffered saline (DPBS) without calcium and magnesium were 
from Invitrogen. Matrigel™ matrix was from BD Biosciences. Charcoal treated FBS was 
from Hyclone. Hygromicin B was from Roche. Dimethyl sulfoxide (DMSO) was form 
Fisher. Dexamethasone, chenodeoxycholic acid (CDCA) and GW4064 were from Sigma. 
Calcitriol (1α, 25-dihydroxyvitamin D3) was from Calbiochem. 9-cis-retinoic acid was 
from Biomel. Rosiglitazone was form Sequoia. TO901317 was from Cayman Chemical. 
Tissue culture flasks, 384 well, black-wall with clear flat bottom tissue culture treated 
and Poly-D-Lysine surface plates were from Corning.  
 
 
Equipment 
 
Matrix WellMate with stacker; 384-channel VPrep® pipetting station; EnVision 2102 
multilabel reader; Biomek® FXР laboratory automation workstation; 384-multichanel 
pipetting head; 10H and 50H pin. 
 
 
Cell Lines  
 
    GR-UAS-bla HEK 293T, VDR-UAS-bla HEK 293T, RXRα-UAS-bla HEK 293T, 
RXRβ-UAS-bla HEK 293T, FXR-UAS-bla HEK 293T, PPARγ-UAS-bla 293-H, LXRα-
UAS-bla HEK 293T, LXRβ-UAS-bla HEK 293T cell lines were from invitrogen. All cell 
lines except RXRα, RXRβ, and FXR were maintained in Matrigel™ matrix precoated 
flasks in the humidified 37°С/5%CO2 incubator. Cell thawing, propagation and freezing 
were performed as described in GeneBLAzer® cell-based assay protocol. 
 
 
Mycoplasma Detection Assay 
 
    MycoAlert® mycoplasma detection kit was from Lonza. At every cell passage, after 
cells were spun down 200 μl cell culture supernatant was taken and centrifuged at 200xg 
for 5 min. 100 μl cleared supernatant was transferred into a white walled 96-well plate as 
test sample. 100 μl of MycoAlert® reagent was added into the sample. After 5 min 
luminescence was read and data was recorded as A. Then 100 μl of MycoAlert® 
substrate was added into the well. After 10 min luminescence was read again and data 
was recorded as B. B/A ratio was calculated. If B/A <1, then it’s negative, otherwise it is 
positive (mycoplasma contaminated). 
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Beta-lactamase Reporter Assay 
 
    Assays were performed as described below in the antagonist assay section. After 
subtracting the average fluorescence intensity of both 460nm and 530nm emission from 
the cell-free control wells, the 460 nm/530 nm ratio was calculated. For EC50 
determination, the ratios were plotted against primary agonist concentration in log scale 
and then analyzed using Prism software (GraphPad Software, Inc., San Diego, CA) 
Sigmoidal dose-response equation with varying slope was used to fit the data and 
generate EC50 value. For compound assay, the percentage of inhibition activity is 
calculated as inhibition activity = 1- (test compound-negative control)/(positive control - 
negative control)*100%. The percentage of inhibition activity is plotted against test 
compound concentration in log scale using Prism one site competition. Z’ factor was 
calculated for each assay plate using Z’ factor = 1-[(3*SDpos. + 3*SDneg.)/(avgpos.-avgneg.)]. 
The assays having Z’ factor of above 0.5 will be accepted.  
 
 
Compound Profiling 
 
    Compounds were initially dissolved in DMSO (10 mM). 384-well master dilution 
plates were made by serially one to three diluting across the plate, starting at 10 mM  to 
0.508 μM in DMSO. 384-multichanel pipetting head with 10H or 50H Pins were used to 
transfer compound from the master dilution plate to assay plates by Biomek® FXР 
laboratory automation workstation. 10H pin carries 25 nl liquid and 50H pin carries 50 nl 
for each transfer. 
 
 
Antagonist Assay 
 
    Cells were harvested at 80% confluence and then re-suspended in assay medium as 
described in chapter 3. Certain concentrations of the cell suspension was dispensed into 
384-well, black-wall, clear bottom assay plates. Plates were centrifuged at 1000 rpm for 1 
minute to help cells attach to the bottom. After 30 min, test compounds were transferred 
into to the plates using Biomek® FXР laboratory automation workstation. The primary 
agonist was applied to stimulate cells after test compounds were transferred. DMSO was 
used as a negative control of compound treatment. The primary agonist was used as a 
positive control of compound treatment. Plates were then incubated in the humidified 
37°С/5%CO2 incubator for 16 hours. LiveBLAzer substrate was loaded after plates were 
cooled down to room temperature. After certain time incubation in the dark the plates 
were read on EnVision 2102 multilabel reader for fluorescence intensity at 460 nm and 
530 nm. 
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Chapter 3. Determing the Specificity of hPXR Antagonists 
 
 
Introduction 
 
Of the 48 human nuclear receptors identified so far, several of them have been 
demonstrated to interplay with PXR. The expression of PXR target gene thus is 
controlled by many physiopathological parameters other than the transcriptional activity 
of PXR. The nuclear receptors involved in functional crosstalk with PXR are 
glucocorticoid receptor (GR), retinoid X receptor (RXR), farnesoid X receptor (FXR), 
peroxisome proliferators-activated receptor (PPAR), liver X receptor (LXR). In addition, 
vitamin D receptor (VDR) and constitutive androstane receptor (CAR) belong to the 
same subfamily of NR as PXR and share many common features with PXR. They are 
also involved in the signaling pathway of PXR target gene regulation. 
 
    Because of the interplay between PXR and these nuclear receptors they share many 
modulators. Many antagonists of these nuclear receptors have been identified so far. 
However, most of them are not specific. When a drug is administrated to antagonize one 
nuclear receptor it often affects the activity of other nuclear receptors involved in other 
signaling pathways as well. So, to identify specific antagonists for PXR is extremely 
important in both clinical and basic research. 
 
    A panel of nuclear receptor cellular assays have been built by Invitrogen through 
stably engineering expression of a fusion protein consisting of the target nuclear receptor 
ligand binding domain (LBD) and Gal4 DNA binding domain (DBD) in a parental HEK 
293 cell line containing the beta-lactamase reporter gene under transcriptional control of 
an upstream activation sequence (UAS) (Figure 3-1). This reporter gene assay is able to 
detect the functional response of a ligand or modulator would have on its receptor. 
Compared with the traditional cell-based reporter gene assay which uses endogenous or 
exogenous full-length receptors, GeneBLAzer eliminates the limitation of selectivity 
because different nuclear receptors can bind to the same or similar response elements and 
ligands [53]. 
 
    In this assay when the ligand binds to the LBD of nuclear receptor the fusion protein 
will bind to the UAS through the DBD of Gal4. This process will activate the 
transcription of beta-lactamase, which will be expressed and secreted into the cytoplasm. 
The protein expression level would be measured by reading the fluorescence intensity of 
a fluorescent substrate which could be dissected by beta-lactamase. When excited the 
substrate emits green light if it’s intact, blue light if it’s been cleaved (Figure 3-2). 
 
    In my experiment eight of the GeneBLAzer cell lines engineered with nuclear 
receptors most functionally related to PXR were used to study the specificity of 92 
previously identified PXR antagonists. These cell lines are GR-UAS-bla HEK 293T, 
VDR-UAS-bla HEK 293T, RXRα-UAS-bla HEK 293T, RXRβ-UAS-bla HEK 293T, 
FXR-UAS-bla HEK 293T, PPARγ-UAS-bla 293-H, LXRα-UAS-bla HEK 293T, LXRβ-
UAS-bla HEK 293T cells.   
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Figure 3-1.  Schematic representation of GeneBLAzer nuclear receptor cell lines.  
The cell stably expresses a fusion protein consisting of the target nuclear receptor ligand 
binding domain (LBD) and Gal4 DNA binding domain (DBD). The fusion protein will 
regulate the expression of beta-lactamase reporter gene which is under the control of an 
UAS response element. When a ligand binds to the LBD of target nuclear receptor beta-
lactamase will express and excrete out of the cell.
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Figure 3-2.  Schematic illustration of FRET assay (Invitrogen protocol).  The BLA 
substrate has two fluoroprobes, coumarin and fluorescein. In the absence of bla 
expression in the cell, the substrate remains intact and is capable of fluorescence 
resonance energy transfer (FRET) and emission of green light. In the presence of bla 
expression, the substrate is cleaved and FRET is disrupted resulting in emission of blue 
light.
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Materials and Methods 
 
 
Cell Culture 
 
    GR was cultured in DMEM supplemented with 10% dialyzed FBS, 0.1 mM NEAA, 25 
mM HEPES (pH 7.3), 100 U/ml penicillin, 100 μg/ml streptomycin, 150 μg/ml 
hygromycin B and 80 μg/ml Zeocin. VDR was cultured in DMEM supplemented with 
10% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3), 100 U/ml penicillin, 100 
μg/ml streptomycin, 80 μg/ml hygromycin and 80 μg/ml Zeocin. RXRα and RXRβ were 
cultured in DMEM supplemented with 10% dialyzed FBS, 0.1 mM NEAA, 25 mM 
HEPES (pH 7.3), 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml hygromycin 
and 100 μg/ml Zeocin; FXR was cultured in DMEM supplemented with 10% dialyzed 
FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3), 100 U/ml penicillin, 100 μg/ml 
streptomycin, 100 μg/ml hygromycin and 100 μg/ml Zeocin.  PPARγ was cultured in 
DMEM supplemented with 10% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3), 
100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml hygromycin, 500 μg/ml 
Geneticin and 1 mM sodium pyrurate. LXRα was cultured in DMEM supplemented with 
10% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3), 100 U/ml penicillin, 100 
μg/ml streptomycin, 80 μg/ml hygromycin and 80 μg/ml Zeocin. LXRβ was cultured in 
DMEM supplemented with 10% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3), 
100 U/ml penicillin, 100 μg/ml streptomycin, 80 μg/ml hygromycin and 15 μg/ml 
blasticidin. 
 
    All cells were maintained between 5% and 95% confluence. Flasks for culturing GR, 
VDR, PPARγ, LXRβ were coated with 1X MatrigelTM matrix and incubated for 15 min 
before plating. 
 
    For any assay process, cells were maintained in assay medium. GR cells were 
harvested and re-suspended in 98% phenol red-free DMEM containing 2% charcoal 
stripped FBS, 0.1 mM NEAA, 25 mM HEPES (pH 7.3), 100 U/ml penicillin, 100 μg/ml 
streptomycin, 1 mM sodium pyrurate. PPARγ cells were maintained in 99% phenol red-
free DMEM with 1% charcoal stripped FBS, 100 U/ml penicillin and 100 μg/ml 
streptomycin. VDR, RXRα, RXRβ, FXR, LXRα and LXRβ cells were maintained in 98% 
phenol red-free DMEM with 2% charcoal stripped FBS, 0.1 mM NEAA, 100 U/ml 
penicillin, 100 μg/ml streptomycin, and 1 mM sodium pyrurate. 
 
 
Assay Optimization  
 
    All cells were tested negative for mycoplasma. Cells were resuspended in assay 
medium for any assays. Four different concentrations of cells were plated. For GR and 
VDR the cell number was 10k, 20k, 30k and 40k, for RXRα and RXRβ the cell number 
was 5k, 10k, 20k and 30k per well. Cells were stimulated with maximum concentration 
of their primary agonist. Plates were incubated at 37°С /5%CO2. After plates were cooled 
down to room temperature different concentration of substrates were loaded. Plates were 
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read for fluorescence intensity at interval times. Response ratio is calculated using the 
460 nm/530 nm ratio of the stimulated wells divided by the unstimulated wells. A bar 
graph was created using Response ratio against different assay conditions. 
 
 
Agonist Dose-response 
 
    Ten different concentrations of agonist dilution were made by serially diluting across 
the plate, starting at the maximum concentration for stimulation (Invitrogen validation 
summary) decreasing in one third in 100% DMSO. Cells were seeded at the number per 
well as determined in the section on assay optimization. The 10H pin tool which carries 
25 nl liquid was used to transfer the agonist into the cell plates. Plates were incubated for 
16 hours. Substrate was loaded and the plates were read at the condition determined as 
described in the section on assay optimization. 460 nm/530 nm ratios for each well were 
calculated, plotted and EC50 was determined as described in chapter two.  
 
 
Compound Assay 
 
Cells (with concentration determined in optimization) were dispensed by WellMate at 
medium speed. Plates were centrifuged at 1000 rpm for 1 min to spin down the cells. The 
50H pin tool was used to transfer from the compounds plate into the cell plates twice 
(100 nl in total). Then agonist plate was transferred once (50 nl). Plates were incubated 
for 16 hours. Substrate was loaded. Plates were read after the incubation time determined 
in assay optimization. Data was analyzed as described in chapter two.  
 
 
Results and Discussion 
 
 
Assay Performance under Variable Conditions 
 
    To optimize the conditions, assays should be performed under different conditions 
including cell numbers, compounds treatment time, DMSO concentration, and substrate 
concentration, loading time and incubation time, plate types. According to the validation 
data from the manufacturer all the cell lines performed the best for 16 hours incubation 
after compounds were added. We used the same incubation time in our assay. Our assay 
was performed in 384-well black wall, clear bottom plates with 25 μl assay volume and 
6X substrate (5 μl) loading. Our system allowed us to use 50H pin which carries 50 nl of 
liquid transferring twice from the stock into the 25 μl cells, which made the final DMSO 
concentration 0.6%. According to the validation data provided by Invitrogen, it doesn’t 
affect the assay performance when DMSO is below 1%. 
 
In order to distinguish the compounds which can inhibit the activation of the 
transcriptional activity of the nuclear receptor by its primary agonist from those that can’t 
inhibit it, it is important to find the condition under which the signals generated by 
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unstimulated wells (neg. control) and stimulated wells (pos. control) are different enough 
that any minor effect on the transactivity will be observable. That is to say the higher 
response ratio (pos. control⁄neg. control) the better.    
 
Among the eight cell lines tested, GR had the highest response ratio of 15 to 22. The 
signal produced by each well is quite consistent. The other three cell lines, VDR, FXR 
and LXRα had a moderate response ratio of about 10 to 15. The signal varied especially 
for FXR and LXRα. The response ratio of the other four cell lines, RXRα, RXRβ, PPARγ 
and LXRβ was relatively low, at around 5 (Figure 3-3). This means that GR is a cell line 
that can generate repeatable results and distinguish compounds that have minor 
differences on inhibition activity. RXRα, RXRβ, PPARγ and LXRβ give the poorest 
performance on the assay. 
  
The cell number is an important condition needed to be determined for our assay. 
When cells were too few, a small amount of beta-lactamase would be produced in each 
well. The signal generated would be relatively low after subtracting the basal signal (cell-
free wells), and it would be more sensitive to background signal and thus produce a big 
error bar. When cells seeded in each well are too many they would reach confluence after 
16 hours incubation which would affect the health of cells and the performance of the 
assay. With the lowest number of cells seeded in each well the highest response ratio was 
generated with the biggest error bars (Figure 3-3). When the cell number increased the 
response ratio decreased a little but with lower error bars. Images were taken after 16 
hours incubation show that the cells were already confluent for the wells that seeded 30k 
cells. We finally choose to use 20k cells per well for GR, VDR, FXR and PPARγ, 10k 
cells per well for  RXRα, RXRβ, LXRα and LXRβ for the following assays because at 
this density cells would not reach confluence in the plates and gave relatively higher 
positive to negative window with lower error bars. 
 
To determine the best substrate incubation time for this assay, plates were read at 
interval times after loading substrate (Figure 3-3). The response ratio window was 
increasing after substrate was loaded until after two hours. The signal window remained 
stable for at least 5 hours for GR, RXRα, RXRβ, LXRα and LXRβ. For VDR the signal 
remained for 3 hours, while for FXR and PPARγ the signal window started to decrease 
after 2 hours. This means we could read the data in this time range that the signal window 
reached highest value and remained stable after substrate were loaded. We finally chose 
the substrate loading time of 1 hour for PPARγ, 1.5 hours for VDR, RXRα and RXRβ, 2 
hours for GR, FXR, LXRα and LXRβ in the following assay. 
 
    Since this assay will read the fluorescence intensity, we have to use the black wall, 
clear-bottom plates for seeding the cells. However, HEK 293 cell is not easy to attach on 
normal plates. Poly-D-Lysine coated plates which helped the cells to attach could be used 
for the assay instead. It is necessary to test whether Poly-D-Lysine would have any 
negative affect on cell growth and assay performance before Poly-D-Lysine plates were 
used in the compound assay. The assay performance in both kinds of plates was tested to 
generate the best condition for each cell line in the assay. Under the optimized conditions 
generated (cell number and substrate loading time) in the previous sections, assays with
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Figure 3-3.  Assay performance with different cell density and substrate loading 
time.  Response ratio (pos ⁄neg) generated by certain cell numbers at certain time after 
substrate loaded. The error bars stand for ± s.d. 
 18
each cell line were performed in both regular plates and Poly-D-Lysine coated plates. The 
Z’ factor which is a statistical parameter measures the quality of a particular assay in 
high-throughput screening showed that all the cell lines perform better in Poly-D-Lysine 
plates except RXRβ because it generated a very high 460 nm⁄530 nm ratio for 
unstimulated wells (cells with DMSO only) (Table 3-1). The images taken after 16 hours 
incubation showed that cells grew as healthy as in regular plates and even denser in Poly-
D-Lysine coating plates than the regular plates even though the cell density is the same 
when seeded (supplementary Figure A-1). However, the pin would damage the coating if 
it touched the bottom when transferring compounds. Cells couldn’t grow on the coating 
damaged area. Fortunately, the readout was not affected by those tiny damaged coating 
areas of the plates. So, Poly-D-Lysine coating plates would be used to screen the 
compounds for GR, VDR, RXRα, FXR, PPARγ, LXRα and LXRβ while regular non-
coating plates would be used for RXRβ. 
 
The tool used to dispense cells in the 384-well plates was also very important to 
generate stable and acceptable assay results. This is because the amount of expressed 
beta-lactamase in each well is dependent on the amount of cells seeded in each well. 384-
channel VPrep® pipette and Matix WellMate at 3 different dispense speeds were tested 
for seeding equal amounts of HEK 293T cells. It turned out that WellMate at middle 
speed can dispense cells equally and evenly in each well (data not shown). 16-well 
automatic hand pipette was used to load substrate. HEK 293T cells are notorious for not 
sticking well on plates. The mechanical force generated when using WellMate or VPrep 
dispensing the substrate would destroy the even distribution of cells which results in 
inconsistent reading of fluorescence intensity.  
    
 
EC50 Determination 
 
EC50 of the agonist is variable in a small range with different experimental conditions. 
We tested the EC50 of the agonist for each nuclear receptor in our experiment under the 
optimized condition for our compound assays. The agonists used are Dexamethasone for 
GR, Calcitriol (1α, 25-dihydroxyvitamin D3) for VDR, 9-cis-retinoic acid for RXRα and 
RXRβ, GW4064 for FXR, Rosiglitazone for PPARγ, TO901317 for LXRα and LXRβ. 
All these agonists were the most potent for its target among the reported agonists.  
 
The agonists used in this assay were recommended by Invitrogen except GW4064. 
Another agonist for FXR, Chenodeoxycholic acid (CDCA) was used first for a dose 
response experiment. It turns out that at the reported maximum concentration of 
stimulation, the transactivity of FXR couldn’t be saturated. After increased the 
concentration applied it showed cytotoxicity to the cell line (supplementary Figure A-2). 
When GW4064 was applied to stimulate FXR, a perfect dose-response curve was 
generated. 
 
After graphing the dose-response curve, the EC50 was determined (Figure 3-4). They 
were 1.09 nM of Dexamethasone for GR, 0.23 nM of Calcitriol for VDR, 15.7 nM and 
16.48 nM of 9-cis-retinoic acid for RXRα and RXRβ respectively, 40.05 nM of GW4064 
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Table 3-1.  Z’ factor of assay in regular and Poly-D-Lysine plates for each cell line.  
 
 GR VDR RXRα RXRβ FXR PPARγ LXRα LXRβ 
regular 0.73 0.54 0.74 0.76 0.82 0.53 0.85 0.73 
P-D-L 0.90 0.88 0.75 0.53 0.81 0.74 0.88 0.84 
 20
VDR: dose-response
-12 -10 -8 -6
0
1
2
3
4
Log [Calcitriol] M
46
0/
53
0 
ra
tio
RXRalpha: dose-response
-10 -8 -6 -4
0
1
2
3
Log [9-cis-RA] M
46
0/
53
0 
ra
tio
GR: dose-response
-12 -10 -8 -6
0.0
0.5
1.0
1.5
2.0
2.5
Log [Dexamethasone]M
46
0/
53
0 
ra
tio
RXRβ: dose-response
-10 -9 -8 -7 -6 -5 -4
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
Log [9-cis-RA] M
46
0/
53
0 
ra
tio
 
FXR: dose-response
-10 -9 -8 -7 -6 -5 -4
0
1
2
3
4
Log [GW 4064] M
46
0/
53
0 
ra
tio
PPARγ: dose - response
-11 -10 -9 -8 -7 -6
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
Log [Rosoglitazone] M
46
0/
53
0 
ra
tio
LXRα: dose - response
-10 -9 -8 -7 -6 -5
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
1.3
1.4
Log [TO901317] M
46
0/
53
0 
ra
tio
LXRβ: dose - response
-10 -9 -8 -7 -6 -5 -4
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
Log [TO901317] M
46
0/
53
0 
ra
tio
 
 
Figure 3-4.  Dose response of the nuclear receptor to its primary agonist.  The EC50 
generated in dose-response were 1.09 nM of Dexamethasone for GR, 0.23 nM of 
Calcitriol for VDR, 15.7 nM and 16.48 nM of , 9-cis-retinoic acid for RXRα and RXRβ 
respectively, 40.05 nM of GW4064 for FXR, 6.32 nM of Rosiglitazone for PPARγ, 23.04 
nM and 87.52 nM of TO901317 for LXRα and LXRβ respectively. The error bars stand 
for ± s. d. 
 21
for FXR, 6.32 nM of Rosiglitazone for PPARγ, 23.04 nM and 87.52 nM of TO901317 for 
LXRα and LXRβ respectively. They were consistent with the reported data. With the 
generated dose-response curve, EC80 could also be determined. A final concentration 
between EC50 and EC80 was used to stimulate the nuclear receptor during the compound 
assay because any inhibition on the agonist induced transactivity in the range between 
EC50 and EC80 will be detected.  
 
 
Selecting Specific Compounds 
 
92 compounds identified as PXR antagonists without cytotoxicity in HepG cells 
(Wenwei Lin, unpublished data) were applied for this beta-lactamase reporter gene assay 
under optimized conditions for specificity using cell lines carrying GR, VDR, RXRα, 
RXRβ, FXR, PPARγ, LXRα and LXRβ respectively.  
 
    Z’ factor was calculated for each plate in the compounds assay (Figure 3-5). The Z’ 
value showed that all of them are greater than 0.6, which means the assay results are 
acceptable. Z’ values for GR and VDR are around 0.9 and quite stable among each assay 
plate. This result is consistent with the one in the section on assay optimization (Figure  
3- 3). Both of them indicate that among the eight cell lines GR and VDR are the ones that 
can generate most reliable results.     
 
    The assay showed that at very low concentration all compounds don’t have any 
inhibition activity on the transcriptional activity of the eight nuclear receptors (data not 
shown). However, these compounds are very potent to PXR (Wenwei Lin, unpublished 
data). This means when administrating at a low concentration, all compounds are 
relatively specific to PXR. 
 
    Among these compounds 21 hits were selected as specific PXR antagonists (Table     
3-2). These compounds, such as SJ000129508, SJ000168394, SJ000200343, 
SJ000254150 etc, didn’t show any inhibition activity for eight nuclear receptors 
(inhibition activity below 20% at 40 μM) but were potent inhibitors for PXR (Figure      
3-6). With a large concentration range, they are specific inhibitors exclusively for PXR. 
We may perform SAR study to identify the structure similarity for these selected PXR 
antagonists in the future. Furthermore, the molecular mechanism of these antagonists to 
PXR needs to be unraveled by using animal models.   
 
    There are two compounds, SJ000025162 and SJ000302340 which showed inhibition 
activity to all the 8 cell lines. However, we were not sure whether the inhibition activity 
is due to its real antagonistic effect to the transcriptional activity of the nuclear receptors 
or the cytotoxicity to the cell lines since we noticed the cells of some wells were very 
sick even dead after 16 hours incubation with compounds administrated (Figure 3-7). To 
test if these compounds were toxic to the cells, cytotoxicity assay was performed on HEK 
293T cell line 24 hours incubation (Wenwei Lin, unpublished data). When SJ000302340 
showed inhibition activity to the nuclear receptors it showed cytotoxicity to HEK 293T 
cells as well. This suggested that whether the compound was antagonist for the nuclear  
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Figure 3-5.  Z’ factor of each assay plate.  Compound assays were performed in 
triplicate. 92 compounds distributed in 3 master solution plates were tested. 
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Table 3-2.  The antagonistic effect of putative hPXR antagonists on various nuclear 
receptors. 
 
Compounds GR VDR RXRα RXRβ FXR PPARγ LXRα LXRβ
SJ000232984         
SJ000274586         
SJ000272971         
SJ000275692         
SJ000232052         
SJ000265390         
SJ000254921         
SJ000254150         
SJ000278772         
SJ000271955         
SJ000241120         
SJ000240467         
SJ000233799         
SJ000249508         
SJ000168475         
SJ000057958         
SJ000289918         
SJ000129508         
SJ000299592         
SJ000176510         
SJ000150475         
SJ000134698         
SJ000156455         
SJ000199270         
SJ000200343         
SJ000158493         
SJ000202840         
SJ000290832         
SJ000168394         
SJ000204230         
SJ000147225         
SJ000057839         
SJ000051863         
SJ000052850         
SJ000056684         
SJ000057241         
SJ000057286         
SJ000057310         
SJ000057626         
SJ000057838         
SJ000043424         
SJ000044857         
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Table 3-2 (continued). 
 
Compounds GR VDR RXRα RXRβ FXR PPARγ LXRα LXRβ
SJ000044880         
SJ000045006         
SJ000045276         
SJ000049443         
SJ000050295         
SJ000051829         
SJ000041640         
SJ000041641         
SJ000041650         
SJ000041678         
SJ000041695         
SJ000041708         
SJ000041720         
SJ000041727         
SJ000009149         
SJ000013041         
SJ000013324         
SJ000024528         
SJ000025162         
SJ000026086         
SJ000031772         
SJ000106379         
SJ000107890         
SJ000101695         
SJ000097801         
SJ000080343         
SJ000079998         
SJ000076745         
SJ000076741         
SJ000076593         
SJ000076585         
SJ000076583         
SJ000075847         
SJ000075766         
SJ000075332         
SJ000075197         
SJ000072854         
SJ000071406         
SJ000065778         
SJ000065777         
SJ000065773         
SJ000061292         
SJ000059479         
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Table 3-2 (continued). 
 
Compounds GR VDR RXRα RXRβ FXR PPARγ LXRα LXRβ
SJ000059461         
SJ000059404         
SJ000059367         
SJ000023063         
SJ000302340         
CMLD001455         
CMLD001197         
 
Note: At the highest concentration administrated (40 μM), compounds that show less 
than 20% inhibition activity are colored white, 20% to 50% are tan, 50% to 80% are 
orange, and above 80% are red. Compounds colored white for all eight NRs are hits for 
the beta-lactamase reporter assay.   
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Figure 3-6.  Specific PXR antagonists.  The compounds didn’t affect the transcriptional 
activity of the 8 nuclear receptors. They showed inhibition activity to PXR even at low 
concentration. The error bars stand for ± s. d. 
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Figure 3-7.  Compounds that showed inhibition activity to all cell lines in the assay.  
SJ000025162 and SJ000302340 showed inhibition activity to all eight nuclear receptors. 
SJ000025162 is 40% toxic to cells at 40 μM. It’s not toxic up to 10μM. It probably inhibited 
the transcriptional activity of at least some of the eight nuclear receptors. SJ000302340 is 
toxic to HEK 293T cell above 10 μM. The inhibition is probably due to its cytotoxicity. The 
error bars stand for ± s. d.
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receptors remains unknown. Compound SJ000025162 showed high inhibition activity but it 
was only 20% toxic to HEK 293T cells at the 40 μM. It suggested that this compound was an 
antagonist for all the nuclear receptors in this assay.   
 
    Most of these compounds can inhibit the activity of RXRβ (60) and PPARγ (47). It might 
suggest some structure similarity of the RXRβ, PPARγ and PXR. Among the 47 compounds 
that showed inhibition activity to PPAR γ most of them are very potent just like their 
inhibition ability to PXR.  Through this reporter gene assay, not only did we identified the 
compounds that are specific to PXR we also got the information of their effects to other eight 
nuclear receptors. It can be used to identify the antagonists for other nuclear receptors as well.  
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APPENDIX. SUPPLEMENTAL DATA FOR CHAPTER 3 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-1.  Cell growth on different assay plates.  10,000 per well LXRα cells were 
seeded in Poly-D-Lysine coated and regular black-wall, clear bottom plate respectively. 
Images were taken after 16 hours incubation.  
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Figure A-2.  Dose response curve of CDCA to FXR.  A. When using reported maximum 
stimulation concentration of CDCA to FXR, the activation activity can not be saturated. B. 
After increased the concentration of CDCA used to stimulate FXR, the agonist showed 
cytocoxicity.
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